Incorporation of Neuland
First API sale of salbutamol sulphate / albuterol sulphate
Neuland goes public
First US FDA audit
Setting up of US Operations
Setting up of Japan Subsidiary
Separate R&D Centre established; EDQM audit of Unit 1
PMDA, Japan approval First NCE approval
Strategic alignment of business towards niche APIs & CMS
10th US FDA audit
R&D facility approved by US FDA
Among first 3 API facilities in India to be audited by CFDA (Unit 1) EDQM Audit of Unit 2
Acquisition of advanced intermediates & API facility
Increased flow of projects from CMS Japan Active emphasis on supply chain de-risking
₹100 Mn+ revenue 75+ live CMS Projects
Unit 3 commercialisation
Laying Strong Foundation
Deepening our Capabilities
Increased Sustainable Growth